Eloralintide
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
Eli Lilly · Phase 1 · Not yet recruiting · Enrollment 60
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Macupatide + placebo | n/r | n/r | n/r | n/r |
| Eloralintide + placebo | n/r | n/r | n/r | n/r |
| Macupatide Dose A + Eloralintide | n/r | n/r | n/r | n/r |
| Macupatide Dose B + Eloralintide | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Macupatide + placebo: endpoint not reported
- Eloralintide + placebo: endpoint not reported
- Macupatide Dose A + Eloralintide: endpoint not reported
- Macupatide Dose B + Eloralintide: endpoint not reported
- Placebo: endpoint not reported